Entresto from Novartis fails its critical phase III in heart failure July 30, 2019 By Lee Landenberger No Comments The failure of Novartis AG's Entresto in a phase III clinical trial staggered the stock (NASDAQ:NVS) somewhat Monday, down just 1.14%, but the real trauma may well be the loss of roughly $2.5 billion in anticipated sales.Read More